{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T18:30:58Z","timestamp":1777919458192,"version":"3.51.4"},"reference-count":0,"publisher":"S. Karger AG","license":[{"start":{"date-parts":[[2008,3,27]],"date-time":"2008-03-27T00:00:00Z","timestamp":1206576000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/karger.com\/pages\/terms-and-conditions"},{"start":{"date-parts":[[2008,3,27]],"date-time":"2008-03-27T00:00:00Z","timestamp":1206576000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/karger.com\/pages\/terms-and-conditions"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neuroendocrinology"],"abstract":"<jats:p>A search for mineralocorticoid binding sites in neural tissue was carried out on the basis of competition by two mineralocorticoid antagonists (spironolactone and glycyrrhetinic acid), a mineralocorticoid agonist (9\u03b1-fluorocortisol) and a pure glucocorticoid (RU 26988). The hippocampus was selected for these studies, in view of its preferential concentration of binding sites for pH]-aldosterone (ALDO) and two glucocorticoids:PH]-corticosterone (CORT) and PH]-dexa-methasone (DEX). Inhibition studies performed with 5 \u00b7 10\u20134\u20135 \u00b7 10\u20139 M spironolactone and with 5 \u00b7 10\u20134\u20135 \u00b7 10\u20138 M glycyrrhetinic acid, showed a dose-response reduction of PH]-ALDO, PH]-CORT and PH]-DEX binding, implying that in brain these compounds did not behave as exclusive ALDO antagonists. Two concentrations of 9\u03b1-fluorocortisol (5 \u00b7 10\u20139 and 2.5 \u00b7 10\u20138 M) preferentially displaced PH]-ALDO in comparison to PH]-DEX or PH]-CORT. Relative binding affinity (RBA) of 9\u03b1-fluorocortisol was also higher for the mineralocorticoid than for the glucocorticoids. RU 26988 (5 \u00b7 10-6\u20132.5 \u00b7 10\u20138 M) gave differential inhibition of the three ligands and its RBA for PH]-DEX site was twice as high as for [3H]- CORT, and three orders of magnitude higher than for PH]-ALDO binding sites, thus clearly separating sites for gluco- and mineralocorticoids. Further evidence for the presence of separate binding molecules for mineralo- and glucocorticoids in hippocampal cytosol was provided by ultracentrifugation on 16\u201341% glycerol gradients containing molybdate, which yielded sedimentation values of 9.88 \u00b1 0.27 for PH]-DEX (n = 5), 10.48 \u00b1 0.27 for PH]-CORT (n = 9) and 11.3 \u00b1 0.13 for PH]-ALDO (n = 7). Whereas data for PH]-CORT and PH]-DEX were not significantly different among themselves, those for [3H]-ALDO were higher (p &lt; 0.05 and p &lt; 0.01, respectively). Moreover, glycerol gradients of cytosol samples incubated with [3H]-ALDO in the presence of a 100-fold excess RU 26988 (circumstances under which 81% of glucocorticoid sites were blocked), revealed a 23% reduction of PH]-ALDO only. These results, based on competition studies, indicate that distinct populations of mineralocorticoid and glucocorticoid sites coexist in brain tissue, and further suggest the tentative identification of the 11.3 S peak as that of the mineralocorticoid binding site in cytosol from hippocampus.<\/jats:p>","DOI":"10.1159\/000123575","type":"journal-article","created":{"date-parts":[[2008,3,28]],"date-time":"2008-03-28T16:47:51Z","timestamp":1206722871000},"page":"354-360","source":"Crossref","is-referenced-by-count":56,"title":["Identification of Mineralocorticoid Binding Sites in Rat Brain by Competition Studies and Density Gradient Centrifugation"],"prefix":"10.1159","author":[{"given":"Hector","family":"Coirini","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisa T.","family":"Marusic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alejandro F.","family":"De Nicola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas C.","family":"Rainbow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruce S.","family":"McEwen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"127","published-online":{"date-parts":[[2008,3,27]]},"container-title":["Neuroendocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/123575","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/karger.com\/article-pdf\/doi\/10.1159\/000123575","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T19:03:35Z","timestamp":1777662215000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000123575"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,3,27]]},"references-count":0,"URL":"https:\/\/doi.org\/10.1159\/000123575","archive":["Portico"],"relation":{},"ISSN":["0028-3835","1423-0194"],"issn-type":[{"value":"0028-3835","type":"print"},{"value":"1423-0194","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,3,27]]}}}